Why Buy Domino’s Pizza Stock?
When you think of growth stocks, you probably imagine technology…
Buy
66
SBHMY Quote, Financials, Valuation and Earnings
Last price:
$8.34
Seasonality move
:
-2.88%
Day range:
$8.34 - $8.34
52-week range:
$6.69 - $9.65
Dividend yield:
2.46%
P/E ratio:
24.58x
P/S ratio:
2.00x
P/B ratio:
1.68x
Volume:
--
Avg. volume:
5
1-year change:
-11.45%
Market cap:
$7.6B
Revenue:
$3.7B
EPS (TTM):
$0.34
Analysts' Opinion
-
Consensus RatingSino Biopharmaceutical has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Sino Biopharmaceutical has an estimated downside of -- from its current price of $8.34.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $8.34.
Fair Value
-
According to the consensus of 0 analysts, Sino Biopharmaceutical has -- downside to fair value with a price target of -- per share.
SBHMY vs. S&P 500
-
Over the past 5 trading days, Sino Biopharmaceutical has overperformed the S&P 500 by 0.48% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Sino Biopharmaceutical does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sino Biopharmaceutical has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Sino Biopharmaceutical reported revenues of --.
Earnings Growth
-
Sino Biopharmaceutical has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Sino Biopharmaceutical reported earnings per share of --.
Enterprise value:
8.4B
EV / Invested capital:
--
Price / LTM sales:
2.00x
EV / EBIT:
9.51x
EV / Revenue:
2.16x
PEG ratio (5yr expected):
3.58x
EV / Free cash flow:
11.76x
Price / Operating cash flow:
10.84x
Enterprise value / EBITDA:
9.51x
Gross Profit (TTM):
$3.1B
Return On Assets:
6.27%
Net Income Margin (TTM):
14.72%
Return On Equity:
10.53%
Return On Invested Capital:
8.21%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Income Statement | ||||||
| Revenue | $3.5B | $3.5B | $2.4B | $906.2M | $1.1B | |
| Gross Profit | -- | -- | -- | $691.1M | $893.5M | |
| Operating Income | -- | -- | -- | $203.7M | $276.9M | |
| EBITDA | -- | -- | -- | $197.6M | $1.3B | |
| Diluted EPS | -- | -- | -- | $0.05 | $1.06 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $4.9B | $3.7B | $3.8B | $3.7B | $3.5B | |
| Total Assets | $9.6B | $8.7B | $9.7B | $9B | $9.2B | |
| Current Liabilities | $1.5B | $1.8B | $2.4B | $3.7B | $3B | |
| Total Liabilities | $3.8B | $3.9B | $3.9B | $4B | $3.4B | |
| Total Equity | $5.9B | $4.8B | $5.8B | $5B | $5.8B | |
| Total Debt | -- | -- | $1.7B | $1.5B | $1.3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | $405.3M | $219.4M | $361.5M | |
| Cash From Investing | -- | -- | -- | -$216.3M | -$627.7M | |
| Cash From Financing | -- | -- | -- | $720.7M | -$117.9M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
SBHMY
Sector
Market Cap
$7.6B
$49.2M
Price % of 52-Week High
86.37%
48.57%
Dividend Yield
2.46%
0%
Shareholder Yield
6.73%
-0.74%
1-Year Price Total Return
-11.45%
-30.94%
Beta (5-Year)
0.525
0.754
Dividend yield:
2.46%
Annualized payout:
$0.20
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$8.34
200-day SMA
Buy
Level
$7.79
Bollinger Bands (100)
Sell
Level
7.79 - 9.03
Chaikin Money Flow
Sell
Level
-54.8K
20-day SMA
Sell
Level
$8.59
Relative Strength Index (RSI14)
Sell
Level
10.45
ADX Line
Neutral
Level
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$8.86
MACD (12, 26)
Sell
Level
-0.17
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Sell
Level
-80K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Buy
CA Score
(Annual)
Level (-0.0244)
Buy
Beneish M-Score
(Annual)
Level (-2.546)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-1.2543)
Buy
Piotroski F Score
(Annual)
Level (4)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm’s biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.
Stock Forecast FAQ
In the current month, SBHMY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SBHMY average analyst price target in the past 3 months is --.
-
Where Will Sino Biopharmaceutical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sino Biopharmaceutical share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Sino Biopharmaceutical?
Analysts are divided on their view about Sino Biopharmaceutical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sino Biopharmaceutical is a Sell and believe this share price will rise from its current level to --.
-
What Is Sino Biopharmaceutical's Price Target?
The price target for Sino Biopharmaceutical over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SBHMY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sino Biopharmaceutical is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SBHMY?
You can purchase shares of Sino Biopharmaceutical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sino Biopharmaceutical shares.
-
What Is The Sino Biopharmaceutical Share Price Today?
Sino Biopharmaceutical was last trading at $8.34 per share. This represents the most recent stock quote for Sino Biopharmaceutical. Yesterday, Sino Biopharmaceutical closed at $8.34 per share.
-
How To Buy Sino Biopharmaceutical Stock Online?
In order to purchase Sino Biopharmaceutical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Companies Are In The VanEck Semiconductor ETF?
There’s a lot to love about the VanEck Semiconductor ETF,…
How High Can Palantir Stock Go?
Palantir Technologies (NASDAQ:PLTR) has been one of the undisputed victors…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
